Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive
Executive Summary
Retacrit – a biosimilar of Amgen's Epogen and J&J's Procrit – will launch at aggressive discounts to the original anemia products in a market where Amgen's already proven there's a tough fight for market share.
You may also be interested in...
Pfizer Delivers On Biosimilars Strategy
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.
Pfizer’s Biosimilar Strategy Might Be Working
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
Lower-Cost Competitors Hit Amgen's Blockbusters
Q1 revenue was roughly in line with expectations, but product sales were lower than consensus as multiple blockbusters faced generic competitors and biosimilars – a scenario the company prepared investors for earlier this year.